Back HCV Disease Progression

HCV Disease Progression

IAS 2015: Fibrosis Regression Linked to Reduced Complications and Death in HIV/HCV Coinfected

HIV/HCV coinfected people with cirrhosis who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver disease complications or die from liver-related causes -- and in some cases fibrosis regression is beneficial even in the absence of a cure -- according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last week in Vancouver. A related study looked at predictors of liver fibrosis progression in HIV/HCV coinfected people, finding that use of certain NRTI "backbone"' antiretroviral drugs and HIV protease inhibitors may increase the risk.

alt

Read more:

DDW 2015: Cirrhosis and Decompensation Are Common Among People with Chronic Hepatitis C

More than one-quarter of Kaiser-Permanente chronic hepatitis C patients developed cirrhosis over 12 years and 40% of these experienced decompensation -- rates higher than expected, according to a presentation at the recent Digestive Disease Week 2015 meeting in Washington, DC. The study also found that cirrhosis and decompensation were associated with comorbid conditions, supporting the idea of hepatitis C as a systemic disease.

alt

Read more:

ASCO 2015: Does Hepatocellular Carcinoma Differ in People with Hepatitis B and C?

Liver cancer patients with hepatitis B at a large U.S. cancer center appeared to have worse disease status than those with hepatitis C, including larger tumors and more extensive liver involvement, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this month in Chicago. Prognosis for the 2 groups was similar, however.

alt

Read more:

Liver Transplants in HIV/HCV Coinfection: Study Underlines Importance of Hepatitis C Treatment

People with HIV and hepatitis C virus (HCV) coinfection were significantly more likely to experience organ rejection than people with either hepatitis C alone or HIV alone after undergoing a liver transplant, according to a review of 11 years of experience with liver transplantation in people with HIV and with hepatitis C in the U.S., published in the June 16 advance edition of the journal Clinical Infectious Diseases.

alt

Read more:

DDW 2015/EASL 2015: Statins Associated with Lower Risk of Death and Liver Decompensation

Hepatitis C patients with liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of U.S. veterans presented at the Digestive Disease Week meeting this week in Washington, DC, and at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Another recent study found that statins were associated with better response to hepatitis C treatment and lower risk of liver cancer.

alt

Read more: